PMID: 11604555Oct 18, 2001Paper

Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia

Anti-cancer Drugs
M TanakaY Ishigatsubo

Abstract

We report a patient who developed CD7+ therapy-related acute myeloid leukemia (t-AML) with trisomy 8 after chemotherapy for AML.

References

Jan 1, 1992·Leukemia Research·S Heim
Jul 20, 1989·The New England Journal of Medicine·C H PuiS B Murphy
Aug 6, 1998·American Journal of Hematology·A SaxenaL F Skinnider

❮ Previous
Next ❯

Citations

Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mukesh K NyatiTheodore S Lawrence

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.